Release Date: November 7, 2025
CME Track Expiration Date: November 7, 2026
Pharmacist Track Expiration Date: February 28, 2027
Activity Overview
Oncology nurses are pivotal members of health care teams in managing new and complex therapies. Their role in patient monitoring, education, and intervention is essential for achieving successful treatment outcomes with antibody-drug conjugates (ADCs). Nurses are uniquely positioned to identify early signs of toxicities, educate patients on possible adverse events, and help mitigate those risks via early medical intervention.
However, many nurses have not received comprehensive education on the relevant biomarkers of ADCs, their mechanisms of action, and the management of adverse events. Given the rapid introduction of ADCs into the clinical landscape, it is critical to address these gaps through continuing education programs. This educational symposium, targeted at oncology nurses, will help bridge these gaps, enabling nurses to provide better patient care and improve clinical outcomes.
This educational activity is an archive of the live presentation held on October 26, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward oncology nurses and nurse practitioners/physician assistants who care for patients with solid tumors.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Discuss the role of ADC therapeutic targets in solid tumors
- Interpret findings from recent clinical trials on ADC therapies and their implications for advanced practice providers
- Apply evidence-based strategies to monitor and manage ADC-specific adverse events during and after treatment
- Describe the clinical considerations of ADC therapy needed to effectively counsel patients

Michelle L. Taylor, ANP-BC
Breast Oncology Nurse Practitioner
Wendt Family Breast Cancer Program
Dignity Health Cancer Institute at St Joseph’s Hospital and
Medical Center
Phoenix, AZ
Disclosures: Speaker: Gilead, Stemline Menarini

Emely Alfaro, DNP, RN, CNS, OCN
Assistant Clinical Professor
UCSF School of Nursing
University of California, San Francisco
Clinical Nurse Specialist, Outpatient Adult Oncology
Adult Infusion Services
San Francisco, CA
Disclosures: Advisor: KORU Medical; Grant/Research Funding: UCSF School of Nursing

Paige Griffith, CRNP
Solid Tumor Advanced Practice Provider Manager
GI Oncology Nurse Practitioner
Skip Viragh Outpatient Cancer Center
The Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins Hospital
Baltimore, MD
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Astellas

Beth Sandy, MSN, CRNP, FAPO
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
Hospital of the University of Pennsylvania
Philadelphia, PA
Disclosures: Advisor/Speaker: Amgen, AstraZeneca, Catalyst, Janssen, Jazz, Lilly, Merck, Pfizer
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.

GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
